Clinical course features of atypical demyelinating optic neuritis: case series

Optic neuritis (ON) can often occur at the onset of a demyelinating autoimmune CNS disease or as one of its clinical manifestations. The introduction of novel laboratory techniques, technical advances in magnetic resonance imaging (MRI), electrophysiologic studies, and ocular imaging have significantly expanded the spectrum of autoimmune optic neuropathies. Identification of different forms of ON based on clinical and instrumental data can lead to early diagnosis of the underlying neurologic disorder. According to current guidelines, one can distinguish between typical ON, which are mainly associated with multiple sclerosis (MS), and atypical ON, which are the main clinical manifestation of neuromyelitis optica spectrum disorders (NMOSD) and diseases associated with myelin oligodendrocyte glycoprotein antibodies (MOGAD). In this paper, we present four clinical cases of atypical ON at the onset of NMOSD and MOGAD and illustrate the high diagnostic value of a multidisciplinary approach.

1. Bennett J, Costello F, Chen J, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023 Jan;22(1):89-100. doi: 10.1016/S1474-4422(22)00187-9

2. Jenkins TM, Toosy AT. Optic neuritis: the eye as a window to the brain. Curr Opin Neurol. 2017 Feb;30(1):61-6. doi: 10.1097/WCO.0000000000000414

3. Gaier ED, Boudreault K, Rizzo JF 3rd, et al. Atypical Optic Neuritis. Curr Neurol Neurosci Rep. 2015 Dec;15(12):76. doi: 10.1007/s11910-015-0598-1

4. McGinley P, Goldschmidt, C, Rae-Grant A. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021 Feb 23;325(8):765-79. doi: 10.1001/jama.2020.26858

5. Zhang Y, Qiu W, Guan H, et al. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol. 2022 Mar 2;13:844155. doi: 10.3389/fneur.2022.844155

6. Foo R, Yau C, Singhal S, et al. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia Pac J Ophthalmol (Phila). 2022 Mar-Apr 01;11(2):184-95. doi: 10.1097/APO.0000000000000513

7. Lennon V, Wingerchuk D, Kryzer T, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17;364(9451):2106-12. doi: 10.1016/S0140-6736(04)17551-X

8. Lennon V, Kryzer T, Pittock S, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7. doi: 10.1084/jem.20050304

9. Häusser-Kinzel S, Weber M. The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Front Immunol. 2019 Feb 8;10:201. doi: 10.3389/fimmu.2019.00201

10. Jacob A, McKeon I, Nakashima, D, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):922-30. doi: 10.1136/jnnp-2012-302310

11. Wingerchuk D, Banwell B, Bennett J, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729

12. Hamid S, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017 Oct;264(10):2088-94. doi: 10.1007/s00415-017-8596-7

13. Flanagan B. Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Contin Lifelong Learn Neurol. 2019;25:815-44. doi: 10.1212/CON.0000000000000742

14. Pröbstel A, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46. doi: 10.1186/s12974-015-0256-1

15. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb 11;82(6):474-81. doi: 10.1212/WNL.0000000000000101. Epub 2014 Jan 10.

16. Peschl P, Schanda K, Zeka B, et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. 2017 Oct 25;14(1):208. doi: 10.1186/s12974-017-0984-5

17. Waters P, Fadda G, Woodhall M, et al. Canadian Pediatric Demyelinating Disease Network. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020 Jan 1;77(1):82-93. doi: 10.1001/jamaneurol.2019.2940

18. Jarius S, Metz I, Konig F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016 Oct;22(12):1541-9. doi: 10.1177/1352458515622986

19. Sechi E, Cacciaguerra L, Chen J, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022 Jun 17;13:885218. doi: 10.3389/fneur.2022.885218

20. Wildemann B, Horstmann S, Korporal-Kuhnke M, et al. Aquaporin-4-und Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Optikusneuritis: Diagnose und Therapie [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment]. Klin Monbl Augenheilkd. 2020 Nov;237(11):1290-305. doi: 10.1055/a-1219-7907 (In Germ.)].

21. Tanaka S, Hashimoto B, Izaki S, et al. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody- positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Mult Scler Relat Disord. 2020 Jun;41:102005. doi: 10.1016/j.msard.2020.102005

22. Akaishi T, Takahashi T, Misu T, et al. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2021 Jul 6;97(1):e1-e12. doi: 10.1212/WNL.0000000000012175

23. Beck R, Cleary P, Backlund J, et al. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994 Nov;101(11):1771-8. doi: 10.1016/s0161-6420(94)31103-1

24. Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology. 2009 Sep 22;73(12):949-53. doi: 10.1212/WNL.0b013e3181b879be

25. Roesner S, Appel R, Gbadamosi J, et al. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012 Aug;126(2):103-8. doi: 10.1111/j.1600-0404.2011.01612.x. Epub 2011 Nov 2.

26. Banwell B, Bennett J, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-82. doi: 10.1016/S1474-4422(22)00431-8

27. Jurynczyk M, Messina S, Woodhall R, et al. Clinical presentation and prognosis in MOGantibody disease: a UK study. Brain. 2017 Dec 1;140(12):3128-38. doi: 10.1093/brain/awx276. Erratum in: Brain. 2018 Apr 1;141(4):e31.

28. Kurane K, Monden Y, Tanaka D, et al. MOG-Ab titer-guided approach for steroid tapering to prevent relapse in children with mog antibody-associated adem diseases: A case report. Mult Scler Relat Disord. 2020 Oct;45:102320. doi: 10.1016/j.msard.2020.102320

29. Deneve M, Biotti D, Patsoura S, et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol. 2019 Sep;46(5):312-8. doi: 10.1016/j.neurad.2019.06.001. Epub 2019 Jun 20.

30. Salama S, Khan M, Shanechi A, et al. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020 Dec;26(14):1854-65. doi: 10.1177/1352458519893093. Epub 2020 Jan 15.

31. Havla J, Pakeerathan T, Schwake C, et al. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation. 2021 May 29;18(1):121. doi: 10.1186/s12974-021-02160-9

32. Dutra B, da Rocha A, Nunes R, et al. Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. Radiographics. 2018 Jan-Feb;38(1):169-93. doi: 10.1148/rg.2018170141

33. Carandini T, Sacchi L, Bovis F, et al. Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021 Sep;54:103118. doi: 10.1016/j.msard.2021.103118

34. Filippatou A, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020 Oct 8;11:540156. doi: 10.3389/fneur.2020.540156

35. Sotirchos E, Filippatou A, Fitzgerald K, et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler. 2020 Oct;26(11):1360-71. doi: 10.1177/1352458519864928

36. Akaishi T, Takahashi T, Fujihara K, et al. Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2021 May;268(5):1938-44. doi: 10.1007/s00415-020-10377-6

37. Wang X, Shi Z, Zhao Z, et al. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. Front Immunol. 2022 Sep29;13:959469. doi: 10.3389/fimmu.2022.959469